Patents by Inventor Vinzent Rolny

Vinzent Rolny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210239712
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.
    Type: Application
    Filed: February 22, 2021
    Publication date: August 5, 2021
    Inventors: Peter Kastner, Andre Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Manuel Dietrich, Ulrich Schotten
  • Publication number: 20210215716
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.
    Type: Application
    Filed: February 22, 2021
    Publication date: July 15, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Peter Kastner, Manuel Dietrich, André Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Ulrich Schotten
  • Publication number: 20210199659
    Abstract: The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.
    Type: Application
    Filed: February 26, 2021
    Publication date: July 1, 2021
    Inventors: Vinzent Rolny, Sandra Rutz, David Morgenstern, Boris Pinchuk, Christina Zimmermann, Martin Klammer, Franziska Sonner
  • Publication number: 20210181211
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for assessing anticoagulation therapy and to methods for predicting the risk of stroke of a subject. Said methods are based on the determination of the amount of TFPI-2 in a sample from the subject.
    Type: Application
    Filed: February 16, 2021
    Publication date: June 17, 2021
    Inventors: Peter Kastner, Andre Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Manuel Dietrich, Ulrich Schotten
  • Publication number: 20210172962
    Abstract: The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 10, 2021
    Inventors: Manuel Dietrich, Peter Kastner, Vinzent Rolny, Ulrich Schotten, Ursula-Henrike Wienhues-Thelen, Andre Ziegler
  • Publication number: 20210156875
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 27, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universitaet Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Jennifer Meessen, Ulrich Schotten
  • Publication number: 20200371114
    Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
    Type: Application
    Filed: December 19, 2019
    Publication date: November 26, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Publication number: 20200300869
    Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 24, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Johann Karl, Peter Kastner, Vinzent Rolny, Andre Ziegler, David Conen
  • Publication number: 20200116708
    Abstract: Disclosed is a method for diagnosing paroxysmal atrial fibrillation in a subject, involving: determining the amount of FABP-3 (Fatty acid binding protein 3) in a sample from a subject suspected to suffer from paroxysmal atrial fibrillation, and comparing the determined amount to a reference amount. The method may further involve the determination of a BNP-type peptide. Also disclosed is a device adapted to carry out the method.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Applicants: Roche Diagnostics Operations, Inc., Maastricht University Medical Center
    Inventors: Johann Karl, Peter Kastner, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Manuel Dietrich, Andre Ziegler, Ulrich Schotten
  • Patent number: 10557858
    Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 11, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Publication number: 20190162737
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: February 1, 2019
    Publication date: May 30, 2019
    Applicants: Roche Diagnostics Operations, Inc., Maastricht University Medical Center
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Serge Masson, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Ulrich Schotten, Vinzent Rolny
  • Publication number: 20180292410
    Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 11, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Farshid Dayyani, Friedemann Krause, Achim Escherich, Birgit Wehnl, Ying He, Vinzent Rolny, Sandra Rutz, Thomas Muley, Felix Herth, Julia Riedlinger
  • Publication number: 20180231557
    Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.
    Type: Application
    Filed: April 13, 2018
    Publication date: August 16, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Friedemann Krause, Vinzent Rolny, Farshid Dayyani, Achim Escherich, Birgit Wehnl, Ying He, Julia Riedlinger, Felix Herth, Thomas Muley
  • Publication number: 20170322225
    Abstract: Subject of the present invention are biomarkers and methods for the identification of risk for subsequent cardiovascular event (e.g. coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, hospitalizations for unstable angina pectotis, cardiac arrest) in patients that have experienced an acute coronary syndrome, comprising the detecting the level of NT-proBNP, homocysteine and CRP.
    Type: Application
    Filed: April 21, 2017
    Publication date: November 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Dieterle, Eric J. Niesor, Rosemarie Kientsch-Engel, Horst Klima, Fabian Model, Gabriela Bucklar, Vinzent Rolny
  • Publication number: 20170227552
    Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 10, 2017
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen